Search
Amylocaine
go.drugbank.com/drugs/DB09088ApprovedWithdrawnDespite the introduction of using cocaine injections for regional anesthesia in 1884, non-addictive substitutes were sought after immediately [L1882]. … Finally, in 1903 the world's first synthetic and non-addictive local anesthetic, amylocaine, was synthesized and patented under the name Forneaucaine by Ernest Fourneau at the Pasteur Institute [L1882]
Lepirudin
go.drugbank.com/drugs/DB00001ApprovedWithdrawn[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking. … [A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022.
Framycetin
go.drugbank.com/drugs/DB00452ApprovedInvestigationalOn hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
Cannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalOn June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalThe FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Iomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigationalIomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use.
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedBy reversibly binding to plasma kallikrein, ecallantide displays a rapid on-rate and a slow off-rate that results in high affinity inhibition in the picomolar range [L1458]. … Hereditary angioedema is a rare autosomal dominant disorder with mutations to C1-esterase-inhibitor (C1-INH) located on Chromosome 11q, resulting in substantially lower levels of C4 and C1-INH activity
Categories: Analgesics, Non-NarcoticPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.